Stockreport

Viridian Therapeutics Prepares for Transformational 2026

Viridian Therapeutics, Inc.  (VRDN) 
PDF - Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track -- Topline [Read more]